The affirmative decision announced Tuesday for the therapy, Casgevy, was widely expected following its December approval in sickle cell disease, but it comes more than two months early.
Casgevy provides a one-time treatment option for transfusion-dependent beta thalassemia patients age 12 and older.
[
add
]
[
|
|
...
]